Johnson & Johnson MedTech Rolls Out Ventricular Arrhythmia Ablation Registry

Johnson & Johnson MedTech, in partnership with Heart Rhythm Clinical and Research Solutions, has introduced the Collaborative Outcomes Registry for Evidence in Ventricular Arrhythmias (CORE-VA).

The prospective, multicenter registry aims to capture contemporary practice patterns in ventricular arrhythmia, including ventricular tachycardia (VT), ablation, and generate high-quality real-world evidence.

VT ablation is a very complex procedure, so it’s usually done by skilled electrophysiologists with advanced treatment strategies. CORE-VA hopes to become the largest data repository of ventricular mapping and ablation workflows, technologies, and patient outcomes.

Francis E. Marchlinski, M.D., Director of Electrophysiology, University of Pennsylvania Health Care System, and CORE-VA Steering Committee Co-Chair, said real-world, standard-of-care registries are crucial to refine techniques, guide training, and expand patient access.

“CORE-VA could illuminate how we can simplify procedures, further identify and avoid risks, and improve access and outcomes for ventricular arrhythmia patients,” Dr. Marchlinski told the press.

Jennifer Currin Ph.D., VP, Scientific Affairs, Electrophysiology, Johnson & Johnson MedTech said CORE-VA is another example of the company’s commitment to building rigorous clinical and scientific evidence to shape the future of arrhythmia care.

“As new technologies are introduced and adopted into clinical practice, this registry will enable us to rapidly collect and analyze real-world data, helping to benchmark outcomes against existing technologies and guide best practices,” said Dr. Currin. “The insights gained through this collaborative effort have the potential to inform clinical standards, training initiatives and future advancements in this complex arrythmia field.”